Aptevo appoints Mary Janatpour as chief scientific officer
Aptevo named Mary J. Janatpour as senior vice president, chief scientific officer in its second-quarter 2026 update.
Janatpour brings more than 25 years of oncology R&D leadership across large biopharma groups and emerging biotech companies.
She will lead research and preclinical development, supporting clinical priorities, the multispecific pipeline, radiopharmaceutical collaboration, and trispecific solid-tumor programs.
APVO•
